Navigation Links
NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
Date:2/11/2008

Clinical Poster Presented at Annual Meeting of the American Academy of

Dermatology

PRINCETON, N.J., Feb. 11 /PRNewswire/ -- NeoStrata today released new clinical data that demonstrates significant benefits in combining microdermabrasion procedures with free acid glycolic acid peels plus bionic/poly-hydroxy acid (PHA) at-home products in improving the appearance and texture of facial skin. The data were highlighted in the Poster Session at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio.

"Microdermabrasion and glycolic acid peels are popular aesthetic procedures for the treatment of photo-damaged skin and acne because they act to exfoliate the epidermis and stimulate cell renewal," said Barbara Green, Vice President for Technology and Clinical Affairs at NeoStrata. "Our research shows there is significant benefit in skin tone, texture and appearance when microdermabrasion is supplemented with glycolic acid peels in a bi-weekly protocol supported by appropriate at-home daily use of bionic and PHA products."

A group of 10 patients applied a 10 percent alpha-hydroxy acid (AHA) cream each evening for two weeks prior to in-office procedures. This conditioning phase served to acclimate the skin to AHAs. Free acid glycolic peels and microdermabrasion treatments were performed alternately every two weeks for a total of four glycolic acid peels and four microdermabrasions over 16 weeks. Patients were given anti-oxidant-rich Bionic/PHA creams post-procedurally, when skin may be sensitive, to calm irritation, hydrate skin and help repair skin barrier function. Patients were also given a collection of bionic/PHA products for at-home use in between procedures, including a cleanser, moisturizer/sunscreen and night cream. The products provided anti-oxidant effects, redness reduction and barrier strengthening.

According to Ms. Green, 100 percent of subjects perceived early benefits after one series of treatments, enhancing patient compliance and commitment to the full protocol. Physicians used a gradual increase in both peel concentration and microdermabrasion vacuum pressure, as tolerated. After the full series of treatments, patients noticed marked improvement in clarity, fine lines and coarse wrinkling. Patients also recorded dramatic improvement in skin firmness and brightness/luminosity.

"The combination approach validates our belief in the benefits of complementary procedures focusing on accelerated exfoliation and cellular renewal -- supplemented with a skin care regimen based on effective yet gentle bionic/PHA technology," said Ms. Green. "An integrated, targeted regimen can provide effective benefits to the overall appearance and texture of skin without the downtime of more invasive cosmetic procedures."

About NeoStrata

The NeoStrata Company, located in Princeton, NJ, develops and markets advanced therapeutic and cosmetic dermatological products through consumer outlets and physicians' offices in the United States and internationally through physicians' offices, pharmacies and spas.


'/>"/>
SOURCE The NeoStrata Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The NeoStrata Company Appoints a New Vice President of Operations
2. NeoStrata Research Validates Anti-Aging Benefits of At-Home AHA Peels As Complement to In-Office Non-Invasive Cosmetic Procedures
3. Radiologists encouraged to look beyond cancer for clinically unseen diseases
4. Clinical depression linked to abnormal emotional brain circuits
5. Preclinical study suggests organ-transplant drug may aid in lupus fight
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Good Clinical Practice Journal Awards: Winners Announced
8. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
9. Study Questions Dead-End Cancer Clinical Trials
10. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
11. Clinical trials present better alternatives for dialysis patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: